摘要
三阴性乳腺癌(TNBC)是由雌激素受体(ER),孕激素受体(PR),和缺乏表达或扩增人表皮生长因子受体2(HER2)所定义的。TNBC的临床病理特点是高分级,高细胞增殖率和更大程度的染色体重排。三阴性乳腺癌患者更可能耐药并且治疗更加困难,并且还经常BRCA1突变。BRCA1基因启动子区的甲基化与减少BRCA1 mRNA水平相关。有BRCA1基因甲基化的TNBC患者与非甲基化的基因相比有更好的无病生存期。从治疗的角度来说,BRCA1基因的表达水平对不同类的化疗有着重要的决定因素。BRCA1功能性肿瘤对DNA损伤的化疗药物如铂类药物过敏。虽然铂类药物是目前广泛使用的在乳腺癌化疗中传统的化疗药物,但是他们的使用有几个缺点。因此,十分令人感兴趣的是可以寻求作为替代的治疗金属为基础的化合物,以克服这些铂类药物的局限性。钌基化合物可能是最有前途的替代铂类药物。本文综述了作为预测指标,以及抗癌钌化合物的一个潜在的药物靶标基因的使用。
关键词: BRCA1;三阴性乳腺癌(TNBC);钌配合物。
Current Cancer Drug Targets
Title:BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Volume: 16 Issue: 7
Author(s): Khwanjira Hongthong and Adisorn Ratanaphan
Affiliation:
关键词: BRCA1;三阴性乳腺癌(TNBC);钌配合物。
摘要: Triple-negative breast cancer (TNBC) is defined by the absence of expression of estrogen receptor (ER), progesterone receptor (PR), and a lack of overexpression or amplification of human epidermal growth factor receptor 2 (HER2). The clinicopathological characteristics of TNBC include a high grading, a high rate of cell proliferation and a greater degree of chromosomal rearrangement. Patients with triple-negative breast cancer are more likely to be drug resistant and more difficult to treat, and are also frequently BRCA1 mutants. Methylation of the BRCA1 promoter region is associated with a reduction of the BRCA1 mRNA level. TNBC patients with a methylated BRCA1 had a better disease-free survival compared with those with non-methylated BRCA1. From a therapeutic perspective, the expression level of BRCA1 has been a major determinant of the responses to different classes of chemotherapy. BRCA1-dysfunctional tumors are hypersensitive to DNA damaging chemotherapeutic agents like platinum drugs. Although platinum based drugs are currently widely used as conventional chemotherapeutic drugs in breast cancer chemotherapy, their use has several disadvantages. It is therefore of interest to seek out alternative therapeutic metal-based compounds that could overcome the limitations of these platinum based drugs. Ruthenium-based compounds could be the most promising alternative to the platinum drugs. This review highlights the use of BRCA1 as a predictive marker as well as for a potential drug target for anticancer ruthenium compounds.
Export Options
About this article
Cite this article as:
Khwanjira Hongthong and Adisorn Ratanaphan , BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666160203113957
DOI https://dx.doi.org/10.2174/1568009616666160203113957 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Involvement of Heat Shock Proteins and Related Molecules in the Resistance to Therapies in Breast and Gynecologic Cancer
Current Cancer Therapy Reviews Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
Current Medicinal Chemistry A Review on Anti-urease Potential of Coumarins
Current Drug Targets Increased NID1 Expression among Breast Cancer Lung Metastatic Women; A Comparative Analysis between Naive and Treated Cases
Recent Patents on Anti-Cancer Drug Discovery In Vivo Human X-ray Investigation of Combined Polysaccharide Based Drug Delivery Systems Prepared for Colonic Delivery
Drug Delivery Letters Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs
Letters in Drug Design & Discovery Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design Editorial (Thematic Issue: Novel Methods and Tools of the Computational Systems Biology in Bioinformatics and Biomedical Informatics)
Current Bioinformatics Soy Isoflavones and Exercise: Possible Benefits for Postmenopausal Womens Cardiovascular Health
Current Women`s Health Reviews Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Patents on Non-Viral Mediated Gene Delivery
Recent Patents on DNA & Gene Sequences T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Withdrawal Notice: Computational Druglikeness Assessment, Synthesis, Characterization and In vitro Biological Activity Evaluation of some Novel Mixed Metal Complexes of 2-(butan-2-ylidene) Hydrazinecarbothioamide
Combinatorial Chemistry & High Throughput Screening Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Protein & Peptide Letters